Seagen EVP Corporate Development - Natasha Hernday

Natasha Hernday

Chief Business Officer

In it to support our values of excellence, integrity, and teamwork. 

Natasha has broad experience in business and corporate development, including licensing, venture capital, and mergers and acquisitions. Since joining Seagen, she has successfully executed numerous licensing and collaboration deals with major pharma partners. She was instrumental in the acquisitions of our manufacturing facility, as well as bringing TUKYSA® (tucatinib) and tisotumab vedotin into our pipeline.

Previously, Natasha was a senior member of the mergers and acquisitions and corporate strategy team at Amgen, where she led a variety of Corporate Development and out-licensing efforts. While at Amgen, she also held roles in research, research project management, and business development finance. 

Natasha earned an M.B.A. from Pepperdine University and a B.A. in Biology from University of California Santa Barbara. She serves as a member of the board of directors for Xoma Corporation and Alpine Immune Sciences Inc., and is a member of the External Advisory Board for the University of Oregon’s Knight Campus for Accelerating Scientific Impact.